Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.46 |
| ▸ | CA1 | P00915 | 6/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6724994 | 0.93 | TRPA1 (0.53) | CA2CA1TRPA1PPARGCA12 | |
| SCHEMBL6465573 | 0.92 | TRPA1 (0.46) | EPHX2NR1H4TRPA1PPARGSMN1; SMN2 | |
| SCHEMBL6255559 | 0.89 | MAPT (0.50) | CA2CA1TRPA1CA12CA9 | |
| SCHEMBL7038032 | 0.88 | TRPA1 (0.56) | TRPA1SMN1; SMN2 | |
| SCHEMBL6430172 | 0.87 | TRPA1 (0.48) | TRPA1PPARGKDM4EGAASMN1; SMN2 | |
| SCHEMBL7021132 | 0.87 | TRPA1 (0.57) | TRPA1POLBSMN1; SMN2 | |
| SCHEMBL6728256 | 0.86 | TRPA1 (0.56) | TRPA1SMN1; SMN2 | |
| SCHEMBL6462371 | 0.86 | MMP13 (0.52) | TRPA1 | |
| SCHEMBL6728070 | 0.86 | TRPA1 (0.46) | TRPA1PPARGKDM4EPOLBSMN1; SMN2 | |
| SCHEMBL6254940 | 0.85 | TRPA1 (0.53) | CA2CA1TRPA1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | HARTER WILLIAM GLEN (US) | 2003-01-02 | — | — | US | claimed |
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | HARTER WILLIAM GLEN (US) | 2003-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | MMP13, MMP3, MMP25 | CA2 213/4885CA1 553/4885EPHX2 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.